Are CTLA4 rs231775 and SH2B3 rs3184504 variants linked to autoimmune thyroid disease susceptibility?

Genetic evidence and susceptibility

• CTLA4 rs231775 (A49G): There is robust genetic epidemiological evidence establishing the CTLA4 rs231775 G allele as a susceptibility locus for autoimmune thyroid diseases (AITD), including Graves' disease (GD) and Hashimoto's thyroiditis (HT). Meta-analyses consistently show that the G allele confers a modest but highly significant risk, increasing GD risk with an odds ratio (OR) of approximately 1.3 to 1.6, which rises to over 2.0 for GG homozygotes. In HT, the association is also observed, with an OR of approximately 1.3 per G allele.
• SH2B3 rs3184504 (R262W): This missense variant is an established shared autoimmune risk locus. Large genome-wide association studies (GWAS) link rs3184504 with general hypothyroidism and AITD susceptibility. Homozygous carriage of the risk allele significantly elevates disease susceptibility, operating as a secondary risk modifier within a broader polygenic autoimmune landscape.

Mechanistic explanations

• CTLA-4 pathway dysregulation: The CTLA4 rs231775 (+49 A>G) variant leads to a Threonine to Alanine substitution that reduces CTLA-4 cell-surface expression and decreases inhibitory signaling on T cells. This loss-of-checkpoint variation permits greater T-cell proliferation and active, vigorous immune targeting of thyroid tissue, which clinically presents as significantly higher titers of both thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb).
• SH2B3 pathway dysregulation: The SH2B3 rs3184504 variant affects the adaptor protein LNK, a negative regulator of cytokine signaling. The risk allele promotes enhanced interferon-gamma production and adaptive immune responses. While it is strongly linked to hypothyroidism and TPOAb levels, direct evidence demonstrating that this variant quantitatively modulates the specific likelihood that these antibodies correspond to active tissue targeting is limited, though biologically plausible through generalized immune dysregulation.

Clinical implications

• Antibodies as active biomarkers: TPOAb and TgAb are well-established clinical biomarkers whose presence in serum directly indicates active immune targeting of thyroid tissue.
• Genotype-phenotype correlation: In patients carrying the CTLA4 rs231775 G allele, detected TPOAb and TgAb are highly likely to reflect active, ongoing immune-mediated destruction of the thyroid. For carriers of the SH2B3 rs3184504 variant, the presence of these antibodies is also highly relevant, though its contribution is mediated through a broader, polygenic autoimmune predisposition.

Bottom line

The CTLA4 rs231775 and SH2B3 rs3184504 variants are established genetic risk factors for autoimmune thyroid disease. The CTLA4 variant directly drives immune-checkpoint dysregulation, making detected TPOAb and TgAb highly reflective of active immune targeting. The SH2B3 variant similarly predisposes to AITD and antibody positivity, though its direct link to active tissue-targeting dynamics remains plausible but less quantitatively defined.